
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.
Up to 90% verified emails and mobile numbers, refreshed weekly.
Evelo Biosciences operates in the Biotechnology Research industry and is headquartered in United States.
Evelo Biosciences has approximately 51-200 employees employees.
Evelo Biosciences is based in Cambridge, MA, United States.
Yes. Evelo Biosciences is a publicly traded company.
You can reach Evelo Biosciences’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.
Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.
An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.
Our team will be in touch soon. If you have any questions, please email us at info@scalelist.com
Just a few more details..
Our team will be in touch soon. If you have any questions, please email us at arnaud@scalelist.com